Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
Harvard University · Harvard University Press · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,953
total citations
- FWCI
- 60.02
- Percentile
- 100%
- References
- 15
Citations per year
Authors
23- CGChristopher G. WillettCorresponding
Harvard University, Harvard University Press, Massachusetts General Hospital
- YBYves Boucher
Harvard University, Harvard University Press, Massachusetts General Hospital
- EDEmmanuelle di Tomaso
Harvard University, Harvard University Press, Massachusetts General Hospital
- DGDan G. Duda
Harvard University, Harvard University Press, Massachusetts General Hospital
- LLLance L. Munn
Harvard University, Harvard University Press, Massachusetts General Hospital
Topics & keywords
Topics
Keywords
- Bevacizumab
- Blockade
- Colorectal cancer
- Vascular endothelial growth factor
- Pericyte
- Medicine
- Cancer research
- Angiogenesis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.